CM Samrat Choudhary Launches Bihar Hemophilia Scheme Worth ₹26.33 Cr
Synopsis
Bihar CM Samrat Choudhary has approved the Mukhyamantri Hemophilia Yojana under the Chief Minister's Medical Assistance Fund, committing ₹26.33 crore in year one to procure Emicizumab for hemophilia patients across the state.
Key Takeaways
Mukhyamantri Hemophilia Yojana approved by the Bihar cabinet under Chief Minister Samrat Choudhary .
Scheme operates under the Chief Minister's Medical Assistance Fund , targeting hemophilia patients across Bihar .
Administrative sanction of ₹26.33 crore approved for first-year expenditure on the drug Emicizumab .
Emicizumab is a proprietary bispecific antibody that mimics clotting-factor function, significantly improving outcomes for hemophilia patients.
The move absorbs high drug costs for enrolled patients, addressing a major barrier to treatment in the state.
Rollout — including Emicizumab procurement and patient enrollment — will be the key implementation milestone to watch in coming months.
A rare disorder that has long slipped through the cracks of public health budgets just got a dedicated lifeline in Bihar. Bihar Chief Minister Samrat Choudhary announced on Wednesday, 30 September 2026 that the state cabinet has approved the Mukhyamantri Hemophilia Yojana — a targeted scheme to fund advanced treatment for hemophilia patients across the state, backed by an initial outlay of ₹26.33 crore.
What the ₹26.33 Crore Covers — and Why Emicizumab Changes Everything
The scheme operates under the existing Chief Minister's Medical Assistance Fund and earmarks the ₹26.33 crore specifically for the procurement of Emicizumab — a bispecific antibody drug classified as a proprietary item — in its first year of implementation. Emicizumab works by mimicking the function of the clotting factor that hemophilia patients lack, dramatically reducing the frequency and severity of bleeding episodes. It is administered subcutaneously and has transformed clinical outcomes globally, but its cost has historically placed it far beyond the reach of most patients in lower- and middle-income settings.
By routing procurement through the state fund, the Bihar government is effectively absorbing that cost for enrolled patients — a significant shift from the status quo where families often bore catastrophic out-of-pocket expenses.
Hemophilia in Bihar — The Scale of the Problem
Hemophilia is a hereditary bleeding disorder in which blood does not clot properly, leaving patients vulnerable to prolonged internal and external bleeding from even minor injuries. It disproportionately affects males and requires lifelong management. Bihar, with one of India's largest and youngest populations, carries a substantial burden of rare genetic disorders that have historically gone underdiagnosed and undertreated due to limited specialist infrastructure and high drug costs.
State governments across India have periodically stepped in with dedicated rare-disease funds, but a scheme focused exclusively on hemophilia — naming the drug by its proprietary formulation and committing a specific crore-level budget — signals a more structured, procurement-ready approach than a general welfare announcement.
NDA4Bihar's Healthcare Push and What Comes Next
Chief Minister Choudhary framed the decision as a 'samvedansheel pahal' — a 'compassionate initiative' — under the broader #CabinetDecisions #NDA4Bihar agenda. The announcement fits a pattern of the Bihar NDA administration using targeted health schemes to demonstrate governance delivery to specific, often underserved, patient communities.
The immediate question is implementation speed: how quickly will Emicizumab procurement be tendered, and how will eligible patients be identified and enrolled? The scheme's real test will be whether the ₹26.33 crore translates into drug in hand — and relief in patients' lives — before the first fiscal year closes.
Point of View
Drug-named budgetary commitments — a more accountable model of rare-disease policy. By naming Emicizumab explicitly and attaching a first-year crore figure, the Bihar government has set a measurable benchmark against which implementation can be judged. For the NDA administration in Bihar, targeted health schemes for underserved patient groups serve a dual purpose: genuine service delivery and visible governance signalling ahead of electoral cycles. The scheme's success, however, will hinge entirely on procurement efficiency and patient-identification infrastructure — areas where state health systems have historically struggled with rare disorders.
NationPress
30 Sept 2026
Frequently Asked Questions
What is the Mukhyamantri Hemophilia Yojana in Bihar?
The Mukhyamantri Hemophilia Yojana is a newly approved Bihar government scheme under the Chief Minister's Medical Assistance Fund that funds treatment for hemophilia patients in the state, with ₹26.33 crore allocated for the drug Emicizumab in its first year.
What is Emicizumab and why is it used for hemophilia?
Emicizumab is a bispecific antibody drug that mimics the clotting factor missing in hemophilia patients, reducing bleeding episodes significantly. It is administered subcutaneously and has transformed hemophilia management globally, though its high cost has limited access in many settings.
How much money has Bihar allocated for the hemophilia scheme?
Bihar has approved an administrative sanction of ₹26.33 crore for the first year of the Mukhyamantri Hemophilia Yojana, specifically for procuring Emicizumab for eligible patients.
Who announced the Bihar hemophilia scheme?
Bihar Chief Minister Samrat Choudhary announced the scheme's approval on 30 September 2026 via a post on X, framing it as a compassionate health initiative under his administration's cabinet decisions.
When will hemophilia patients in Bihar start receiving treatment under the new scheme?
The scheme has received administrative approval; the next steps involve tendering for Emicizumab procurement and enrolling eligible patients. The rollout timeline in the coming months will determine when patients actually receive the drug.
